Startups
Enleofen was founded as a spin-out from NHCS, SingHealth and Duke-NUS Medical School focused on developing new anti-fibrotic therapies.
Overview
Employees
1-10
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 9, 2020 | Singapore biotech could get more than $1B from Boehringer Ingelheim under partnership | Enleofen’s lead product candidate – in studies to enable the company to seek regulatory approval to move it into the clinic – is ENx108A an antibody that targets IL-11 and has been shown preclinically to reverse organ dysfunction by targeti... |
| Singapore biotech could get more than $1B from Boehringer Ingelheim under partnership | One of Germany’s largest drugmakers is partnering with a Southeast Asian company to develop drugs for fibrotic diseases. Boehringer Ingelheim, a privately owned company based in Ingelheim am Rhein, Germany, said Thursday that it had partner... |
Reviews 0
FAQ about Enleofen
What has the press written about Enleofen?
Parsers VC has collected 3 articles mentioning Enleofen, among them “Singapore biotech could get more than $1B from Boehringer Ingelheim under partnership” (Jan 9, 2020) and “Singapore biotech could get more than $1B from Boehringer Ingelheim under partnership”.
Is Enleofen still active?
Yes, Enleofen is active; its latest activity on Parsers VC dates from Jun 17, 2020.